Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Highlights

Global Bioenergies launches its makeup brand


Global Bioenergies was created in 2008 by Marc Delcourt at Genopole. In his company’s R&D laboratory, the Cosmetic Formulation Unit created in November 2019 has conjugated bio-based ingredients and long-lasting performance in an unprecedented line of mascaras and eye shadows.
Press release >
LAST - Makeup by Global Bioenergies LAST - Makeup by Global Bioenergies

Global Bioenergies has achieved a historic step in its commercial development with the launch of LAST®, a makeup brand combining natural ingredients and long-lasting performance.

Marc Delcourt - CEO of Global BioenergiesInterview with Marc Delcourt, founder and CEO of Global Bioenergies

Can you tell us more about your manufacturing process for the isododecane used in your makeup products?

Marc Delcourt : “In 2019, we created a Cosmetic Formulation Unit in our laboratory in Évry. That unit developed our first prototypes of eye cosmetics, for which isododecane is the main ingredient. Isododecane is an assembly of three isobutylene molecules that we produce from renewable resources such as beets, straw or wood shavings, among others.

Microorganisms transform the sugars of these plant resources into isobutylene via an exclusive, patented synthetic biology process that we have been developing over the last ten years. Those prototypes have been perfected and industrialized in partnership with one of Europe’s main makeup manufacturers. We thus are bringing to the cosmetics market a line of products using bio-based isododecane. That molecule is the primary ingredient in long-lasting mascaras and lipsticks, representing as much as 25 to 50% of their formulas. To date, isododecane has always been petroleum-based.”

Your products prove that “natural” and “long-lasting” can walk hand-in-hand?

Marc Delcourt : “Natural makeup products already exists, but ‘long-lasting’ has never really been applicable to them. Our products are indeed the first to genuinely unite those two qualities. Isododecane is the key and majority ingredient in long-lasting makeup. By biosourcing the isododecane and completing the formula with other natural ingredients, we are able to attain a high rate of naturality (greater than 90%) while maintaining performance equal to that of the best makeup products on the market.”

Why did you choose to invest in the cosmetics sector?

Marc Delcourt : “The objective of our industrial biology company is to provide an alternative to the petrochemistry industry. We are not abandoning biofuels, but it is currently difficult to compete against petroleum-based fuels as they remain very inexpensive. We thus chose to invest in cosmetics, a sector where customers are clamoring for natural products and thus willing to pay the price needed to cover the higher cost of bio-based isododecane. We needed to acquire all the competencies necessary for cosmetics: formulations, marketing, packaging, e-commerce, regulations. But the agility of our company made that possible.”

What are your commercial development perspectives?

Marc Delcourt : “We are currently moving into commercialization. All turnover to date has resulted from partnerships. We will now generate direct recurrent revenue. The initial run will count about 300,000 units, which, at 20 euros per unit, represents a market value of six million euros. We foresee a scale increase starting in 2022 with the sale of makeup ingredients to market leaders to energize the move to naturality for the entire sector. Thereafter, we’ll enlarge our activities to other cosmetics specialties, like hair care and dermo-cosmetics.”

A full range of products


Tested under dermatological control, the brand LAST® currently comprises three product categories: mascaras, eyebrow fillers and eye shadows, all offering a duration of at least 24 hours.
Counting color choices, the range counts 18 references currently under production in a French facility.

Commercialization in France and England at the website www.colors-that-last.com will begin in June for the mascaras and eye shadows, and extend to lipsticks (14 colors) for the fall season.

The product line targets active women looking for long-lasting makeup and all women prioritizing natural products.

The mascaras (9 mL) will sell for €25, the eyebrow fillers (2.5 mL) for €18 and the eye shadows (5 mL) for €24.

The line comprises vivid shades like yellow, green and blue, as well as more classic shades like taupe, brown, kaki and black.

Article posted on 6 May 2021

Share
Global Bioenergies launches its makeup brand

Latest news


Neurons representation - Cells affected by CMT

Gene therapy for Charcot-Marie-Tooth disease makes headway

A gene therapy for Charcot-Marie-Tooth disease has been shown to be efficacious in an animal-model study cosigned by a research team created through Genopole support.

Discover
NEB France celebrate 10 years @ Genopole

New England Biolabs France Celebrates 10 Years!

Its French affiliate arrived at Genopole in 2011 and to mark its 10th anniversary in France, the company invites you to participate in monthly activities to be held throughout 2021.

Discover
Visualization and quantification by MTBench technology of protein-protein interactions observed at Opera Phenix + in a cell line.

Seeing in high resolution at the Structural Biology Platform

With the support of Genopole & the University of Évry and to enrich its technological offer, the Structural Biology Platform has acquired the Opera Phenix Plus high content screening (HCS) system.

Discover
MSCA COFUND 2020 - ApogeeBio Laureate

COFUND-MSCA2020 : ApogeeBio chosen by the EC

Submitted by Genopole and its on-site partners, the ApogeeBio project for research grants has been selected by the European Commission for Marie Skłodowska-Curie Actions co-funding (MSCA-Cofund-2020).

Discover
Genhotel -  fibroblastes, cancer & Polyarthrite

Metabolic reprogramming involved in rheumatoid arthritis and cancer

The researchers from GenHotel (University of Évry-Paris Saclay, Genopole) have shed light on certain aspects common to rheumatoid arthritis and cancer.

Discover
AB Science L. Gros

Multiple sclerosis and COVID-19: promising results from AB Science

AB Science has been announcing a series of positive results concerning the efficacy of its product, masitinib, in such pathologies as multiple sclerosis, severe asthma resistant to oral steroids, COVID-19 and amyotrophic lateral sclerosis.

Discover
Placton - Tara Oceans

Bioinformatics and Tara Oceans

A team from the Genomics Metabolics Laboratory (Genoscope – CEA/CNRS/University of Évry) has developed a bioinformatics method for environmental genomics analyses able to identify species and associations of species.

Discover
Globules rouges - Avancées scientifiques

CRISPR-Cas9 for blood and metabolic diseases – Integrare

In an article published in Nature Communications, an Integrare team headed by Dr. Mario Amendola has described an innovative genome editing strategy aimed at modifying hematopoietic stem cells.

Discover
Généthon - Genopole's Laboratory

Treating more patients with gene therapies – Généthon

A Genethon team has successfully inhibited immune response to adeno-associated virus vectors, and in so doing, opened potential paths for treating more patients with gene therapies.

Discover
COVID-19 Disease Map

A single interactive map for all that is known on COVID-19

The objective for this latter is to build a sole referential comprising the totality of scientific knowledge on SARS-CoV-2/human-host interactions and thus contribute to the identification of therapeutic possibilities.

Discover
cellular membrane

Mapping membrane nanotubes – Lambe

A team from the Genopole-accredited Laboratory for Analysis and Modeling in Biology and the Environment (Lambe) has developed an experimental technique to study cell membrane nanotubes. These largely unknown structures play an essential role in cellular biomolecule transport.

Discover
Laboratory

Toward the industrialization of gene therapies -Polytheragene

Polytheragene is developing a polymer that will improve upon the current market standards for the production of viral particles for therapeutics. The polymer will be used by Genethon and Yposkesi to enhance the bioproduction of gene therapy vectors.

Discover
Jean Weissenbach

Jean Weissenbach: a portrait

Jean Weissenbach, a pioneer in France for the exploration of the human genome and a scientific icon at Genopole, talks about his career in an interview published 18 March 2020 in CNRS News.

Discover
cellular membrane

A nanopore to identify amino acids – Lambe

A team from the Laboratory for Analysis and Modeling in Biology and the Environment (Lambe – University of Évry/University of Cergy-Pontoise/CNRS) used a natural aerolysin nanopore to successfully identify 13 of the 20 amino acids that make up proteins.

Discover
Genopole - European projects

Green light from Europe for the Genopole-coordinated project GEN.ERA

Le projet européen GEN.ERA*, coordonné par Genopole, est sélectionné par la Commission européenne. Il vise à renforcer par une coopération entre clusters, l’internationalisation d’entreprises du secteur de la génomique au-delà du continent européen.

Discover
actus

New accomplishment in gene therapies

A clinical trial for a gene therapy to treat a severe immunodeficiency has provided highly promising initial results.

Discover
View all >
With support